Increased TIGIT expression correlates with impaired NK cell function in diffuse large B-cell lymphoma

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Natural killer (NK) cells play a crucial role in antitumor immunity.
• NK cell dysfunction is implicated in DLBCL pathogenesis and immune evasion.

Purpose of the Study:

• To investigate NK cell status in DLBCL patients.
• To elucidate the role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) in regulating NK cells within the DLBCL microenvironment.
• To evaluate TIGIT blockade as a potential therapeutic strategy.

Main Methods:

• Analysis of NK cell populations and TIGIT family molecule expression (TIGIT, CD226, CD96) in DLBCL patients versus healthy controls using multiparametric flow cytometry.
• Assessment of NK cell function, including cytotoxicity and cytokine secretion.
• Evaluation of TIGIT blockade effects on NK cell activity in vitro and in vivo models.

Main Results:

• DLBCL patients showed reduced NK cell numbers and impaired function compared to controls.
• Upregulated TIGIT and downregulated CD226 expression were observed on NK cells in DLBCL.
• TIGIT blockade significantly restored NK cell cytotoxicity against DLBCL cells.

Conclusions:

• Aberrant TIGIT pathway signaling contributes to NK cell dysfunction in DLBCL.
• Targeting TIGIT represents a promising approach to enhance NK cell-mediated antitumor immunity in DLBCL.
• Restoring NK cell function via TIGIT blockade could overcome tumor immune escape in DLBCL.